Patient Enrollment Complete in Phase 3 Study of aminolevulinic acid HCI 10% (Ameluz, Biofrontera) for the Treatment of AK on the Extremities, Neck, and Trunk
Biofrontera Inc. has completed enrollment in its Phase 3 clinical trial evaluating aminolevulinic acid hydrochloride (Ameluz) with photodynamic therapy (PDT) for the treatment of mild to moderate actinic keratoses (AKs).